Department of Rheumatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), Melbourne, Victoria, Australia.
Intern Med J. 2023 Mar;53(3):311-317. doi: 10.1111/imj.15908. Epub 2022 Aug 25.
Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.
羟氯喹（HCQ）及其近亲氯喹（CQ）最初被用作抗疟药物，但现在在风湿病学、皮肤病学和免疫学中被广泛用于治疗自身免疫性疾病。HCQ 被认为具有比 CQ 更好的长期安全性，因此更常用。HCQ 在治疗包括系统性红斑狼疮（SLE）在内的结缔组织疾病中具有重要作用，它提供有益的免疫调节而没有明显的临床免疫抑制作用。HCQ 还可以辅助治疗炎症性关节炎，包括类风湿关节炎（RA）。关于 COVID-19 中 HCQ 毒性的争论，使那些经常开具 HCQ 的医生不得不讨论其潜在毒性。因此，我们回顾了 HCQ 的不良影响谱，以提供有关该治疗药物在临床实践中的指导。
